SPECIAL NOTICE

We are working on upgrading our websites and despite our best endeavours have experienced census type calamities for almost a week now. Our apologies, we hope to have all problems resolved by Monday August 15th.

InvestoGain Australia

SEARCH BY NAME

BROWSE

Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

SEARCH BY CODE

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

RESPIRI LIMITED (RSH)

Listed on ASX

SHARE PRICES

(discontinued 17 July 2020)

Former (or subsequent) names

 FROMTO
RESPIRI LIMITED07/12/2015
ISONEA LIMITED29/08/201107/12/2015
KARMELSONIX LTD27/11/200629/08/2011
SALUS TECHNOLOGIES LIMITED15/12/200427/11/2006
Q-VIS LIMITED15/12/2004

Shareholder links

Our website ranking of RSH: rating 1
(1 out of 5)
COMPANY WEBSITE:

 

REGISTRY:

Computershare, Yarra Falls, 452 Johnston Street, Abbotsford VIC 3067

Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)
Fax : +61 3 9473 2500
RegistryWebsite RegistryEmail

Company details

Address: Level 9, 432 St Kilda Road Melbourne, Vic 3004
Tel:  +61 3 9602 3366 Fax: 

Date first listed: 14/07/2000
Company Secretary: Alastair Beard
Sector: Health Care Equipment & Services Industry Group: XHJ
Activities: Medical research and development company

The suspension of trading in the securities of Respiri Limited will be lifted immediately following the release by RSH of an announcement regarding a capital raising.

14/04/2020

The company signed a Joint Development Agreement with Phenix Health, an Australian based health workflow designer for virtual healthcare settings. Under the terms of the JDA, Respiri will work to ensure that the wheezo eHealth SaaS monitoring platform is integrated into the Phenix proprietary telehealth platform, patient dashboards and asthma management plans. Phenix will we be responsible for providing patients already diagnosed with asthma the option of using wheezo to help monitor their condition and so providing healthcare beyond the clinic setting.

14/04/2020

The Company is providing its loyal shareholders with an opportunity to participate in the SPP to raise up to $1million (before costs) by the issue of up to 18,181,819 SPP Shares, with the capacity to accept an additional $1 million (before costs) pursuant to the Oversubscription. Under the SPP Offer, each Eligible Shareholder may apply for up to $30,000 worth of new Shares at $0.055 per Share. Applications may be made in parcels of $1,000, $2,000, $5,000, $10,000, $15,000, $20,000, $25,000 and $30,000 worth of SPP Shares. Investors should note that the Company will only be accepting Applications under the SPP Offer from Eligible Shareholders that have not disposed of any of their shares between the re-commencement of trading following the Opening of the SPP Offer at 6pm on 9 April 2020 and the Closing of the SPP Offer on 1 May 2020.

14/04/2020

The company's general meeting will be held on 26 May 2020 at 2pm (Melbourne time). Registration is from 1pm. The web address for the meeting is: https://web.lumiagm.com with meeting ID 385-292-319.

09/04/2020

The company issues a prospectus for an offer to Eligible Shareholders to participate in a Share Purchase Plan by subscribing for up to $30,000 worth of new Shares at an at an offer price of $0.055 (5.5 cents) per Share to raise up to $1 million (before costs), with the capacity to accept up to an additional $1 million (before costs) pursuant to the Oversubscription. The prospectus is also for a separate offer to remain open for up to 3 months from the close of the SPP Offer, to subscribe for any SPP Shares not taken up pursuant to the SPP Offer to be issued at an offer price of $0.055 per Shortfall Share, being the price at which SPP Shares have been offered under the SPP Offer.

09/04/2020

The company releases the following: a prospectus for a Share Purchase Plan (SPP) closing on 1 May 2020, and a notice of an Extraordinary General Meeting (EGM) to be held on 26 May 2020.

09/04/2020

The company releases an Appendix 2A.

06/04/2020

The company releases an updated notice of Proposed issue of Securities - RSH.

06/04/2020

The company releases a notice of Proposed issue of Securities - RSH.

03/04/2020

The company announces the successful completion of a share placement raising $2.0 million before costs. The company also announces a share purchase plan to raise up to a further $1 million (before costs). The company may, subject to shareholder demand, accept oversubscriptions under the SPP for an additional $1 million (before costs). The SPP offer to eligible shareholders provides the opportunity to purchase up to $30,000 of new Respiri shares under the SPP offer at $0.055 per share. The SPP is limited to shareholders with a registered address in Australia and New Zealand who were shareholders as at the record date of 25 March 2020. It is anticipated that the SPP offer will be open for three weeks from 10 April 2020 to 01 May 2020.

26/03/2020

The securities of Respiri Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of RSH, pending the release of an announcement regarding the proposed capital raising.

19/03/2020

The suspension of trading in the securities of Respiri Limited will be lifted immediately following the release by RSH of an announcement regarding a capital raising.

30/07/2019

The company has successfully conducted a $3.4 million capital raising via a private placement to sophisticated and professional investors. The placement price is 10.0 cents per fully paid ordinary shares in the capital of the company. The fund raising has had broad support from a number of Respiri's long-term investors and was underpinned by leading family offices including the Smedley Family Office. The placement also includes $100,000 from the directors of the company.

30/07/2019

The securities of Respiri Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of RSH, pending the release of an announcement regarding a capital raising.

29/07/2019

The suspension of trading in the securities of Respiri Limited (the "Company") will be lifted immediately, following the announcement of a capital raising by the Company.

19/05/2016

The company is pleased to announce that it will provide eligible shareholders with the opportunity to participate in a 1 for 2 renounceable entitlement offer of new RSH shares at an issue price of $0.03 per New Share to raise up to $4.3M. The Entitlement Offer has been fully underwritten by the Company's mandated brokers Patersons Securities Limited.

19/05/2016

The securities of Respiri Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement by the Company.

18/05/2016

name changed from iSonea Limited

07/12/2015

ASX Announcements (courtesy of ASX)

 

Your comments

Please read our Terms before viewing comments.

 

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...


    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    DATEDIRECTORNUMBERPRICEAMOUNT
    19/02/2020Marjan Mikel235,294$0.085$20,030
    18/02/2020Nicholas Smedley320,274$0.084$26,903
    13/02/2020Thomas Duthy200,000$0.085$17,040
    13/02/2020Nicholas Smedley268,426$0.084$22,548
    27/11/2019Marjan Mikel561,478$0.089$49,972

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT
    Nicholas SmedleyChairman30/10/2019
    Marjan MikelManaging Director, CEO25/11/2019
    Alastair BeardCEO29/10/2019
    Peter VaughanCFO05/10/2011
    Thomas DuthyIndependent Director24/10/2018
    David AshmoreNon Exec Director19/06/2014
    John Ribot-de-BresacNon Exec Director04/02/2014
    Tim OldhamDirector06/01/2014

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    Bruce ThompsonNon Exec Director27/11/201810/02/2020
    Mario GattinoNon Exec Director01/12/201725/11/2019
    Ross Blair-HoltNon Exec Chairman28/11/201415/11/2019
    Leon L'HuillierNon Exec Chairman04/02/201418/12/2018
    Mark ZiirsenChairman30/05/201827/11/2018
    Brendan MasonDirector30/05/201827/11/2018
    Stephen TunnellManaging Director, CEO04/02/201401/12/2017
    Bruce MathiesonNon Exec Director04/02/201428/11/2014
    Michael ThomasCEO14/06/201101/05/2014
    Ross HaghighatChairman20/10/201004/02/2014
    Jerome KortenCEO20/10/201004/02/2014
    Ross MacDonaldDirector03/04/201204/02/2014
    David DantzkerDirector21/03/201204/02/2014
    Stewart WasherChairman27/07/201206/01/2014
    Fabio PannutiDirector20/10/201031/03/2012
    Paul HopperDirector20/10/201031/03/2012
    Phillip HainsCFO21/11/200605/10/2011

    Date of first appointment, title may have changed.